Cargando…

The risk of melanoma with rasagiline compared with other antiparkinsonian medications: A retrospective cohort study in the United States medicare database

PURPOSE: Compare the risk of melanoma between initiators of rasagiline or other antiparkinsonian drugs (APDs) in a Parkinson's disease (PD) population. METHODS: A retrospective cohort study was conducted in the US Medicare claims research database (2006–2015) in adults aged ≥65 years with PD cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johannes, Catherine B., Saltus, Catherine W., Kaye, James A., Calingaert, Brian, Kaplan, Sigal, Gordon, Mark Forrest, Andrews, Elizabeth B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321028/ https://www.ncbi.nlm.nih.gov/pubmed/35224798 http://dx.doi.org/10.1002/pds.5422

Ejemplares similares

Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States
por: Saltus, Catherine W., et al.
Publicado: (2019)

Corrigendum to “Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States”
por: Saltus, Catherine W., et al.
Publicado: (2019)

Antipsychotics dosage and antiparkinsonian prescriptions
por: Acquaviva, Eric, et al.
Publicado: (2007)

A STUDY OF PROPHYLACTIC VALUE OF ANTIPARKINSONIAN DRUG
por: Behere, P.B., et al.
Publicado: (1983)

Importance of Nanoparticles for the Delivery of Antiparkinsonian Drugs
por: Silva, Sara, et al.
Publicado: (2021)

Epidemiology of Adult Soft-Tissue Sarcomas in Germany
por: Saltus, Catherine W., et al.
Publicado: (2018)

Rasagiline in treatment of Parkinson’s disease
por: Nayak, Lakshmi, et al.
Publicado: (2008)

Antiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder
por: Massari, Caio M., et al.
Publicado: (2017)

Antiparkinsonian Agents in Investigational Polymeric Micro- and Nano-Systems
por: Paccione, Nicola, et al.
Publicado: (2022)

Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia
por: Matthews, Dawn C., et al.
Publicado: (2021)

The role of rasagiline in the treatment of Parkinson’s disease
por: Leegwater-Kim, Julie, et al.
Publicado: (2010)

Rasagiline Withdrawal Syndrome in Parkinson’s Disease
por: Solla, Paolo, et al.
Publicado: (2022)

Treatment Patterns, Costs, and Survival among Medicare-Enrolled Elderly Patients Diagnosed with Advanced Stage Gastric Cancer: Analysis of a Linked Population-Based Cancer Registry and Administrative Claims Database
por: Karve, Sudeep, et al.
Publicado: (2015)

Trends in Antiparkinsonian Medication Use in New Zealand: 1995–2011
por: Pitcher, T. L., et al.
Publicado: (2014)

Parkinson's disease diffusion MRI is not affected by acute antiparkinsonian medication
por: Chung, Jae Woo, et al.
Publicado: (2017)

Antiparkinsonian effects of the "Radiprodil and Tozadenant" combination in MPTP-treated marmosets
por: Michel, Anne, et al.
Publicado: (2017)

Adjunctive therapy in Parkinson’s disease: the role of rasagiline
por: Gaines, Kathryn D, et al.
Publicado: (2012)

Linezolid and Rasagiline – A culprit for serotonin syndrome
por: Hisham, Mohamed, et al.
Publicado: (2016)

The Antiparkinsonian and Antidyskinetic Mechanisms of Mucuna pruriens in the MPTP-Treated Nonhuman Primate
por: Lieu, Christopher A., et al.
Publicado: (2012)

Antiparkinsonian drugs as potent contributors to nocturnal sleep in patients with Parkinson’s disease
por: Taguchi, Soutarou, et al.
Publicado: (2021)

Orthostatic Hypotension and Antiparkinsonian Drugs: A Systematic Review and Meta-analysis
por: Nimmons, Danielle, et al.
Publicado: (2021)

Antiparkinsonian medication masks motor signal progression in de novo patients()
por: Brzezicki, Maksymilian A., et al.
Publicado: (2023)

Viral Failure Among Persons Living with HIV Initiating Dolutegravir-Based vs. Other Recommended Regimens in Real-World Clinical Care Settings
por: Nance, Robin, et al.
Publicado: (2017)

Deciphering the Actions of Antiparkinsonian and Antipsychotic Drugs on cAMP/DARPP-32 Signaling
por: Bonito-Oliva, Alessandra, et al.
Publicado: (2011)

Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical Implications
por: Miguelez, Cristina, et al.
Publicado: (2017)

Predictive Factors of Antiparkinsonian Drug Reduction after Subthalamic Stimulation for Parkinson’s Disease
por: SAMURA, Kazuhiro, et al.
Publicado: (2019)

Time until modification of antiparkinsonian therapy in a group of patients from Colombia
por: Valencia-Vásquez, Aníbal, et al.
Publicado: (2023)

Engineering of Reductive Aminases for Asymmetric Synthesis of Enantiopure Rasagiline
por: Zhang, Kai, et al.
Publicado: (2021)

Risk of Acute Liver Injury Associated with the Use of Moxifloxacin and Other Oral Antimicrobials: A Retrospective, Population-Based Cohort Study
por: Kaye, James A, et al.
Publicado: (2014)

Rapid preparation process of antiparkinsonian drug Mucuna pruriens silver nanoparticle by bioreduction and their characterization
por: Arulkumar, Subramanian, et al.
Publicado: (2010)

1,5-Benzodiazepin-2(3H)-ones: In Vitro Evaluation as Antiparkinsonian Agents
por: Ortíz de Zárate, Ana, et al.
Publicado: (2021)

From a Parkinson's disease expert: Rasagiline and the Future of Therapy
por: Lakhan, Shaheen E
Publicado: (2007)

Role of rasagiline in treating Parkinson’s disease: Effect on disease progression
por: Malaty, Irene A, et al.
Publicado: (2009)

Striking Neurochemical and Behavioral Differences in the Mode of Action of Selegiline and Rasagiline
por: Harsing, Laszlo G., et al.
Publicado: (2023)

c-Abl Inhibition Exerts Symptomatic Antiparkinsonian Effects Through a Striatal Postsynaptic Mechanism
por: Zhou, Yu, et al.
Publicado: (2018)

LUHMES Cells: Phenotype Refinement and Development of an MPP(+)-Based Test System for Screening Antiparkinsonian Drugs
por: Beliakov, Sergei V., et al.
Publicado: (2023)

Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy
por: Lecht, Shimon, et al.
Publicado: (2007)

Rasagiline and Rapid Symptomatic Motor Effect in Parkinson’s Disease: Review of Literature
por: Pistacchi, Michele, et al.
Publicado: (2013)

An analysis of patterns of distribution of buprenorphine in the United States using ARCOS, Medicaid, and Medicare databases
por: Hsu, Zhi‐Shan, et al.
Publicado: (2023)

Motor Improvement-Related Regional Cerebral Blood Flow Changes in Parkinson's Disease in Response to Antiparkinsonian Drugs
por: Taguchi, Soutarou, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_aq1v1nt3seohtvbka9mn0eg53t